Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days af...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Völker, Linus A., Kaufeld, Jessica, Miesbach, Wolfgang, Brähler, Sebastian, Reinhardt, Martin, Kühne, Lucas, Mühlfeld, Anja, Schreiber, Adrian, Gaedeke, Jens, Tölle, Markus, Jabs, Wolfram J., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Bauer, Frederic, Westhoff, Timm H., Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bieringer, Markus, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Gäckler, Anja, Kribben, Andreas, Schwenger, Vedat, Schoenermarck, Ulf, Roeder, Maximilian, Radermacher, Jörg, Bramstedt, Jörn, Morgner, Anke, Herbst, Regina, Harth, Ana, Potthoff, Sebastian A., von Auer, Charis, Wendt, Ralph, Christ, Hildegard, Brinkkoetter, Paul T., Menne, Jan
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Thrombosis and Hemostasis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362370/
https://ncbi.nlm.nih.gov/pubmed/32634236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001973
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires